STAMFORD, Conn., May 13 /PRNewswire/ -- Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE),today announced that it has been selected by the U.S. Army's Telemedicine & Advanced Technology Research Center (TATRC) to present the Company's latest technologies at the TATRC exhibit during this year's American Telemedicine Association Conference
"We are honored to have been selected by TATRC to present our industry leading medical devices at this premier conference," stated Zargis CEO, John Kallassy. "This presentation represents the first major marketing event for Zargis' new, award winning tele-auscultation platforms."
In addition to participating with TATRC at this conference, Zargis will also be demonstrating its newly introduced ZargisTelemed™ platform, which allows recordings from electronic stethoscopes to be easily transmitted between healthcare professionals via the Internet.
For more information about Zargis' tele-auscultation tools or to arrange a demonstration call 609-488-4608.
TATRC is an office of the headquarters of the U.S. Army Medical Research and Materiel Command (USAMRMC). TATRC fosters research on health informatics, telemedicine/m-Health, medical training systems, and computational biology, and promotes and manages science and engineering in other key portfolios. Through an extensive network of partners, TATRC is focused at both ends of the research spectrum, exploring models of high risk and innovative research, and putting research findings into the hands of warfighters while looking toward wider civilian utility. TATRC augments core medical research programs through special funding and partnership opportunities.
About Zargis Medical Corp.
Zargis is a global medical device company focused on improving health outcomes and cost-effectiveness through diagnostic support software and innovation. Zargis is majority-owned by Speedus Corp. (Nasdaq: SPDE), and both 3M Company and Siemens Corporate Research, a division of Siemens AG (NYSE: SI), hold equity positions.
For additional information about Zargis or Speedus Corp., contact Peter Hodge at 888.773.3669 (ext. 23) or email@example.com, or visit the following Web sites: www.zargis.com and www.speedus.com.
Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.
SOURCE Speedus Corp.
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All